Fatty-Acid Catabolism Promotes T-cell Revitalization in Melanoma [Immunology]
A hypoxic and hypoglycemic tumor microenvironment induces the metabolic reprogramming of CD8+ TILs. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: Immunology Source Type: research
Gammaproteobacteria Metabolize Gemcitabine to Promote Chemoresistance [Chemotherapy]
Most human PDACs harbor intratumor Gammaproteobacteria that may promote gemcitabine resistance. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: Chemotherapy Source Type: research
Tigecycline May Selectively Target Leukemic Stem Cells in CML [Leukemia]
Tigecycline inhibits mitochondrial oxidative phosphorylation to target leukemic stem cells (LSC). (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: Leukemia Source Type: research
GPC2 May Be an Immunotherapeutic Target in High-Risk Neuroblastoma [Neuroblastoma]
A GPC2-targeting antibody–drug conjugate promotes tumor regression in a high-risk neuroblastoma PDX. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: Neuroblastoma Source Type: research
Talimogene Laherparepvec Enhances the Efficacy of PD-1 Blockade [Melanoma]
Talimogene laherparepvec plus pembrolizumab achieved response in 62% of patients with melanoma. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: Melanoma Source Type: research
Mitogen and Stress Signal Memory Regulates Daughter Cell Proliferation [Cell Division]
CCND1 and p53 transmitted to daughter cells in mitosis determine if cells are proliferative or quiescent. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: Cell Division Source Type: research
Checkpoint Inhibitors Spur Changes in Trial Design [News in Depth]
Given the success of checkpoint inhibitors and the desire to test them in combination with other immunotherapies and targeted therapies, hundreds of clinical trials have been launched. To most efficiently study these agents, researchers and the FDA are exploring the use of novel endpoints, the use of new preclinical models, and adaptive trial designs. However, the cost and demands associated with the conduct of increasingly sophisticated early-phase clinical trials are putting smaller companies and some academic medical centers at a disadvantage. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: News in Depth Source Type: research
Noted [News in Brief]
A collection of recently published news items. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Gemtuzumab Ozogamicin Makes a Comeback [News in Brief]
After being pulled from the market 7 years ago, gemtuzumab ozogamicin has been reapproved by the FDA, this time for adults newly diagnosed with acute myeloid leukemia, as well as patients 2 years of age and older with relapsed/refractory disease. The CD33-targeting antibody–drug conjugate can be given as a single agent or in combination with chemotherapy. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Liquid Biopsy Technique May Allow Early Screening [News in Brief]
Researchers have developed a new liquid biopsy technique that may allow screening for certain types of cancer. The technique can detect tumor mutations from the small amount of blood DNA present early in the disease. In four types of cancer, the technique's overall sensitivity was between 56% and 83%, and it could pinpoint 62% of patients with early-stage cancer. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Approved Drugs Might Work in More Cancers [News in Brief]
Researchers in the Netherlands presented preliminary results from a multiarm precision medicine trial at the recent ESMO 2017 Congress in Madrid, Spain. The trial, which matches patients with approved drugs based on mutations in their tumor and tissue type, has the potential to uncover treatment options for patients who have exhausted standard therapies, as well as those with rare cancers. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
FDA Approves First Biosimilar to Treat Cancer [News in Brief]
The FDA approved the VEGF inhibitor bevacizumab-awwb for the treatment of five types of cancer: nonsquamous non-small cell lung cancer, metastatic colorectal cancer, cervical cancer, renal cell carcinoma, and glioblastoma. A biosimilar to bevacizumab, the agent is the first such drug approved for the treatment of cancer. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
People [News in Brief]
Peter Pisters, MD, MHCM, and Michael Teitell, MD, PhD, are highlighted. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
In This Issue [In This Issue]
(Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: In This Issue Source Type: research
ACTRT1 Inhibits Hedgehog Signaling to Suppress Basal Cell Carcinoma [Translocations]
Coding or enhancer mutations in ACTRT1 reduce its expression to drive basal cell carcinoma. (Source: Cancer Discovery)
Source: Cancer Discovery - November 1, 2017 Category: Cancer & Oncology Tags: Translocations Source Type: research
